Amgen Inc (HKSE:04332)
HK$ 1761 0 (0%) Market Cap: 1.18 Til Enterprise Value: 1.58 Til PE Ratio: 36.22 PB Ratio: 20.20 GF Score: 92/100

Amgen Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 15, 2022 / 05:40PM GMT
Release Date Price: HK$1850
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good morning. Thanks, everyone, for joining us. Really pleased to have the Amgen team with us. We have Peter Griffith, CFO; and Dave Reese, Head of R&D. With that, earlier this year -- actually, I'm going to turn it over to you, Peter, first to start with any opening comments.

Peter H. Griffith
Amgen Inc. - Executive VP & CFO

Great. Thank you, Salveen. Good morning, everyone. And thank you, Goldman, for the 43rd Healthcare Conference. That means I did my math. That means it must have started about when Gene Sykes graduated from college. So I know he's not here, so I can get away with that.

So listen, at Amgen, we always begin with patients. Our mission at Amgen, we're a mission-driven company, is to discover, develop, manufacture and distribute and deliver first-in-class and best-in-class medicines to patients all over the world. And the first quarter was a great indicator that we're on track to deliver against our long-term objectives and, more importantly, against

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot